In this video, Arvind N. Dasari, MD, MS, discussed the results of the CheckMate 8HW trial in which nivolumab and ipilimumab were compared with nivolumab monotherapy for microsatellite instability-high ...
IMCR's strong balance sheet, with over $800 million in liquid assets, positions them well for future R&D or even a potential ...
The global PD-L1 biomarker testing market is on a strong growth trajectory, rising from USD 777.2 million in 2025 to USD 1,690.8 million by 2035, at a CAGR of 8.1% during the forecast period.PD-L1 ...
From breakthrough treatments to AI-driven diagnostics, healthcare is evolving faster than ever. With increasing healthcare ...
Phase III PRESTIGE-AF trial shows that direct oral anticoagulants significantly lower the risk of ischemic stroke in ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback